# OncoC4 Announces First Patient Dosing in Phase 1 Clinical Trial of ONC-783 for the Treatment of Advanced Solid Tumors

- Link: https://www.thailand-business-news.com/pr-news/oncoc4-announces-first-patient-dosing-in-phase-1-clinical-trial-of-onc-783-for-the-treatment-of-advanced-solid-tumors
- Published: 2026-08-17T19:00:00+07:00
- Author: PR Newswire

|   |

_— ONC-783 is the first-and-only clinical-stage T-cell engager targeting a cancer-
specific glycoform of CD24 (neoCD24) —_

_— Subcutaneous formulation designed to provide gradual systemic exposure, potentially
mitigating CRS risk —_

ROCKVILLE, Md., Aug. 17, 2026 /PRNewswire/ — OncoC4 Inc., a late clinical-stage 
biopharmaceutical company developing novel medicines for cancer and neurodegenerative
diseases, today announced dosing of the first patient following the clearance of
the Investigational New Drug (IND) application for a Phase 1 clinical trial (NCT07408258)
of ONC-783, the company’s investigational T-cell engager developed based on the 
proprietary neoCD24 platform.

"This milestone demonstrates OncoC4’s leading position in developing first-in-class
cancer therapeutics," said Dr. Yang Liu, CEO and Chief Scientific Officer, "CD24
is expressed in nearly 70% of human cancers ^(1), and abnormal glycosylation in 
malignant cells produces the neoCD24 epitope that is largely absent from the normal
tissues. By exploiting this cancer-specific epitope, ONC-783 is designed to maximize
selectivity for tumor cells while minimizing the risk of on-target/off-tumor toxicity
that has limited other T-cell engagers."

ONC-783 is the world’s first and only clinical stage T-cell engager targeting the
cancer-specific glycoform of CD24 (neoCD24). The drug candidate is designed to address
the limitations of existing immunotherapies by selectively targeting the tumor-specific
epitope while redirecting T cells for potent anti-tumor activity. Preclinical studies
have demonstrated broad anti-tumor activity for ONC-783 across multiple solid tumor
and hematologic malignancies, including pancreatic cancer, lung cancer, breast cancer,
colorectal cancer, ovarian cancer, glioblastoma, and mantle cell lymphoma, which
supports the potential of ONC-783 as a treatment across multiple tumor types. In
addition, a subcutaneous formulation was developed for ONC-783 to enable gradual
systemic exposure and provide a potential safety advantage compared with intravenously
administered T-cell engagers.

"We are extremely excited to partner with OncoC4 to explore the potential of targeting
neoCD24 to bring clinical benefit for cancer patients with limited treatment options,"
added Dr. Aiwu Ruth He, Professor of Medicine and medical oncologist at Columbia
University Irving Medical Center in New York City. "Advanced solid tumors remain
a significant challenge, and this innovative mechanism offers a promising new approach
for patients who have progressed or intolerant to standard therapy_._"

ONC-783 is being tested in ONC-783-001, a Phase 1 trial in the US for patients with
advanced solid tumors. The first study patient was successfully dosed at Columbia
University Irving Medical Center. The treatment was well tolerated. No severe Adverse
Events, Cytokine Release Syndrome, or Immune Effector Cell-Associated Neurotoxicity
Syndrome have been observed to date. OncoC4 will continue the innovation in cancer
immunotherapy and remain committed to the development of first-in-class therapeutics
to address the unmet needs in cancer treatments.

**About ONC-783-001**

ONC-783-001 is a Phase 1 open-label, dose-escalation study in the United States (
U.S.) to evaluate the safety, pharmacokinetics (PK) and efficacy of ONC-783 as a
single agent in patients with advanced/metastatic solid tumors, focusing on colorectal
cancer, ovarian cancer, pancreatic cancer, or breast cancer. OncoC4 has engaged 
several clinical centers across the U.S. to recruit patients for ONC-783-001 including
Columbia University Irving Medical Center and The University of Texas MD Anderson
Cancer Center. The clinical trial registration number is NCT07408258.

**About the NeoCD24 Platform**

CD24 is expressed in nearly 70% of human cancers^(1), along with a significant level
of expression also in normal tissues, where it plays a key role in regular cell 
growth, tissue maintenance, and immune system function. Targeting CD24 as a cancer
treatment has been challenging due to the lack of selectivity to tumor cells. OncoC4
has discovered that abnormal glycosylation in malignant cells produces the neoCD24
epitope, a tumor-specific antigen that is largely absent from normal tissues, enabling
the development of cancer-specific therapeutics targeting CD24. OncoC4 is developing
several first-in-class cancer treatments based on the neoCD24 platform.

**About OncoC4**

Based in Rockville, Maryland, OncoC4 is a privately held, late clinical-stage biopharmaceutical
company that is actively engaged in the discovery and development of novel biologics
for the treatment of cancer and immunological diseases. OncoC4’s pipeline features
assets with first-in-class and best-in-class potential targeting both novel and 
well-validated targets across oncology and immunological diseases. Among them, AI-
081 is a fully owned bispecific antibody candidate targeting PD-1 and VEGF. ONC-
841 is a first-in-class anti-SIGLEC-10 antibody currently in a Phase 2 trial for
oncology indications and a Phase 1 trial for neurodegenerative diseases. OncoC4 
has a strategic collaboration with BioNTech to co-develop gotistobart (BNT316/ONC-
392), a tumor microenvironment-selective Treg depletion candidate targeting CTLA-
4, in multiple solid tumor indications, including an ongoing pivotal clinical trial
in squamous non-small cell lung cancer.

More information: [www.oncoc4.com](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4752831-1&h=693874858&u=https%3A%2F%2Fwww.oncoc4.com%2F&a=www.oncoc4.com).

**CONTACTS**

Media Relations
Pan Pan[media@oncoc4.com](https://www.thailand-business-news.com/pr-news/media@oncoc4.com)

Investor Relations
Ryan Cui[ir@oncoc4.com](https://www.thailand-business-news.com/pr-news/ir@oncoc4.com)

References

 1. Ju-Han Lee, Seo-Hee Kim, Eung-Seok Lee, Young-Sik Kim CD24 overexpression in cancer
    development and progression: a meta-analysis Oncol Rep 2009 Nov;22(5):1149-56. 
    doi: 10.3892/or_00000548.

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [OncoC4 Announces First Patient Dosing in Phase 1 Clinical Trial of ONC-783 for the Treatment of Advanced Solid Tumors ](http://www.prnasia.com/story/archive/5026733_AE26733_0?rand=184833)
